Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety of Sirolimus in LAM

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Age 18 or older~* Signed and dated informed consent~* Diagnosis of LAM based on compatible chest CT scan and a) biopsy or cytology consistent with LAM, or b) presence of tuberous sclerosis, angiomyolipoma or chylous pleural effusion; or c) a VEGF-D level of at least 800 pg/ml~* Forced expiratory volume in one second (FEV1) of 70% or less of predicted value after administration of a bronchodilator~Exclusion Criteria:~* Known allergy to sirolimus~* History of heart attack, angina, or stroke due to clogging, narrowing, and hardening of the arteries and blood vessels~* Significant hematologic or hepatic abnormality (transaminase levels greater than three times the upper limit of normal, HCT less than 30%, platelets less than 80,000/cubic mm, adjusted absolute neutrophil count less than 1,000/cubic mm, total white blood cell count less than 3,000/cubic mm)~* Intercurrent infection at the time treatment with sirolimus begins~* Any surgery involving entry into a body cavity or requiring three or more sutures within 8 weeks of initiation of study drug~* Use of an investigational drug within the 30 days prior to random assignment~* Uncontrolled hyperlipidemia~* Previous lung transplant or currently on lung transplant list~* Unable to attend scheduled study visits~* Unable to perform pulmonary function tests~* Creatinine levels greater than 2.5 mg/dl~* Chylous ascites severe enough to affect diaphragmatic function~* Pleural effusion severe enough to affect pulmonary function, as determined by the study physician~* History of acute pneumothorax within the 2 months prior to study entry~* History of malignancy within the 2 years prior to study entry (except for squamous or basal cell skin cancer)~* Use of estrogen containing medication within the thirty days prior to randomization~* Unable or unwilling to use adequate contraception~* Pregnant, breastfeeding, or plans to become pregnant within the next 2 years

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Active Agent (Sirolimus) (Type: EXPERIMENTAL): Participants receive sirolimus daily for 1 year and are followed with serial pulmonary function tests, 6-minute walk tests, and symptom and QOL questionnaires over a 2-year period.
- Placebo Arm (Type: PLACEBO_COMPARATOR): Participants receive placebo daily for 1 year and followed with serial pulmonary function tests, 6-minute walk tests, and symptom and QOL questionnaires over a 2-year period.

Based on this trial design, predict the completion outcome and termination type (if applicable).